Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study

Leukemia

Volumn 13, Issue 3, 1999, Pages 335-342

  Amylon, M D ^a,n   Shuster, J ^b   Pullen, J ^c   Berard, C ^d   Link, M P ^a   Wharam, M ^e   Katz, J ^m   Yu, A ^f   Laver, J ^g   Ravindranath, Y ^h   Kurtzberg, J ⁱ   Desai, S ^j   Camitta, B ^k   Murphy, S B ^l  

^a STANFORD UNIVERSITY   (United States)

^b Pediat Oncol Grp Stat Office   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d St Jude Children's Research   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MUS Carolina   (United States)

^h CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

ⁱ DUKE UNIVERSITY   (United States)

^j CROSS CANCER INSTITUTE   (Canada)

^k Midwest Children's Cancer Center   (United States)

^l CHILDREN'S MEMORIAL HOSPITAL   (United States)

^m UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁿ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Asparaginase; Leukemia; Lymphoma; Pediatric; T cell

Indexed keywords

ANTIINFECTIVE AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; HYDROCORTISONE; METHOTREXATE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; STATISTICAL ANALYSIS; SURVIVAL RATE; T LYMPHOCYTE;

EID: 0032973925     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401310     Document Type: Article

References (58)

1. Tsukimoto I, Wong KY, Lampkin BC. Surface markers and prognostic factors in acute lymphoblastic leukemia. New Engl J Med 1975; 292: 828-832.
2. Murphy SB, Aur RJ, Simone JV, George S, Mauer AM. Pretreatment cytokinetic studies in 94 children with acute leukemia: relationship to other variables at diagnosis and to outcome of standard treatment. Blood 1977; 49: 683-691.
3. Gupta S, Good RA. Markers of human lymphocyte subpopulations in primary immunodeficiency and lymphoproliterative disorders. Semin Hematol 1980; 17: 1-29.
4. Frei E III, Schnabel FM Jr, Goldin A. Comparative chemotherapy of AKR lymphoma and human hematological neoplasia. Cancer Res 1974; 34: 184-193.
5. Ohnuma T, Arkin H, Minowada J, Holland JF. Differential chemotherapeutic susceptibility of human T-lymphocytes and B-lymphocytes in culture. J Natl Cancer Inst 1978; 60: 749-752.
6. Verhoef V, Fridland A. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res 1985; 45: 3646-3650.
7. Lauer SJ, Pinkel D, Buchanan GR, Sartain P, Cornet JM, Krance R, Borella LD, Casper JT, Kun LE, Hoffman RG, Camitta BM. Cytosine arabinoside/cyclophosphamide pulses during continuation therapy for childhood acute lymphoblastic leukemia: potential selective effect in T-cell leukemia. Cancer 1987; 60: 2366-2371.
8. Quddus FF, Leventhal BG, Boyett JM, Pullen DJ, Crist WM, Borowitz MJ. Glucocorticoid receptors in immunological subtypes of childhood acute lymphoblastic leukemia cells: a Pediatric Oncology Group study. Cancer Res 1985; 45: 6482-6486.
9. Pieters R, Kaspers GJ, Van Wering ER, Huismans DR, Loonan AH, Hahlen K, Veerman AJ. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 1993; 7: 392-397.
10. Roper M, Crist WM, Metzgar R, Ragab AH, Smith S, Starling K, Pullen J, Leventhal B, Bartolucci AA, Cooper MD. Monoclonal antibody characterization of surface antigens in childhood T-cell lymphoid malignancies. Blood 1983; 61: 830-837.
11. Crist WM, Grossi CE, Pullen DJ, Cooper MD. Immunologic markers in childhood acute lymphocytic leukemia. Semin Oncol 1985; 12: 105-121.
12. Borowitz MJ, Dowell BL, Boyett JM, Falletta JM, Pullen DJ, Crist WM, Humphrey GB, Metzgar RS. Monoclonal antibody definition of T-cell acute leukemia. A Pediatric Oncology Group study. Blood 1985; 65: 785-788.
13. Borowitz MJ, Dowell BL, Boyett JM, Pullen DJ, Crist WM, Quddus FM, Falletta JM, Metzgar RS. Clinicopathologic aspects of E-rosette negative T-cell acute lymphocytic leukemia. A Pediatric Oncology Group study. J Clin Oncol 1986; 4: 170-177.
14. Raimondi SC, Behm FG, Robertson PK, Pui CH, Rivera GK, Murphy SB, Williams DL. Cytogenetics of childhood T-cell leukemia. Blood 1988; 72: 1560-1566.
15. Carroll AJ, Crist WM, Link MP, Amylon MD, Pullen DJ, Ragab AH, Buchanan GR, Wimmer RS, Vietti TJ. The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990; 76: 1220-1224.
16. Bash RO, Crist WM, Shuster JJ, Link MP, Amylon M, Pullen J, Carroll AJ, Buchanan GR, Smith RG, Baer R. Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TALI locus. A Pediatric Oncology Group study. Blood 1993; 81: 2110-2117.
17. Raimondi SC. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 1993; 81: 2237-2251.
18. Steinherz PG, Siegel SE, Bleyer WA, Kersey J, Chard R Jr, Coccia P, Keikin S, Lukens J, Neerhout R, Nesbit M, Miller DR, Reaman G, Sather H, Hammond D. Lymphomatous presentation of childhood acute lymphoblastic leukemia. Cancer 1991; 68: 751-758.
19. Vannier JP. Childhood non-Hodgkin's lymphomas: clinical and therapeutic aspects. Biomed Pharmacother 1988; 42: 263-271.
20. Amylon MD, Link MP, Murphy SB. Malignant T-cell and other non-Hodgkin's lymphoma of childhood. In: Voute PA, Barrett A (eds). Cancer in Children, 2nd edn. Springer Verlag: New York, 1986, pp 152-163.
21. Crist WM, Shuster JJ, Falletta J, Pullen DJ, Berard CW, Vietti TJ, Alvarado CS, Roper MA, Prasthofer E, Grossi CE. Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group study. Blood 1988; 72: 1891-1897.
22. Shuster JJ, Falletta JM, Pullen DJ, Crist WM, Humphrey GB, Dowell BL, Wharam MD, Borowitz M. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990; 75: 166-173.
23. Borowitz M. Immunologic markers in childhood acute lymphoblastic leukemia. Hematol Oncol Clin North Am 1990; 4: 743-752.
24. Crist W, Shuster J, Look T, Borowitz M, Behm F, Bowman P, Frankel L, Pullen J, Krance R, Steuber P, Camitta B, Amylon M, Link M, Land V. Current results of studies of immunophenotype-, age-, and leukocyte-based therapy for children with acute lymphoblastic leukemia. Leukemia 1992; 6: 162-167.
25. Pui CH, Behm FG, Crist WM. Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82: 343-362.
26. Sen L, Borella L. Clinical importance of lymphoblasts with T markers in childhood acute leukemia. New Engl J Med 1975; 292: 828-832.
27. Coccia PF, Kersey JH, Gajil-Peczalska KJ, Krivit W, Nesbit ME. Prognostic significance of surface marker analysis in childhood non-Hodgkin's lymphoproliferative malignancies. Am J Hematol 1976; 1: 405-417.
28. Belpomme D, Mathé G. Clinical significance and prognostic value of the T-B immunological classification of the human primary acute lymphoid leukemias. Lancet 1977; 1: 555-558.
29. Heideman RL, Falletta JM, Mukhopadhayay MS, Fernbach DJ. Lymphocytic leukemia in children: prognostic significance of clinical and laboratory findings at time of diagnosis. J Pediatr 1978; 92: 540-545.
30. Sallan SE, Ritz J, Pesandro J, Gelber R, O'Brien C, Hitchcock S, Coral F, Schlossman SF. Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood 1980; 55: 395-402.
31. Greaves MF, Janossy G, Peto J, Kay H. Immunologically defined subclasses of acute lymphoblastic leukemia in children: their relationship to presentation features and prognosis. Br J Haematol 1981; 48: 179-197.
32. Pullen DJ, Boyett JM, Crist WM, Falletta JM, Roper M, Dowell B, Van Eys J, Jackson JF, Humphrey GB, Metzgar RS, Cooper MD. Pediatric Oncology Group utilization of immunologic markers in the designation of acute lymphocytic leukemia subgroups: influence on treatment response. Ann NY Acad Sci 1984; 428: 26-48.
33. Crist WM, Grossi CE, Pullen DJ, Cooper MD. Immunologic markers in childhood acute lymphocytic leukemia. Semin Oncol 1985; 12: 105-121.
34. Pui CH, Behm FG, Singh B, Schell MJ, Williams DL, Rivera GK, Kalwinsky DK, Sandlund JT, Crist WM, Raimondi SC. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 1990; 75: 174-179.
35. Pullen DJ, Sullivan MP, Falletta JM, Boyett JM, Humphrey GB, Starling KA, Land VJ, Dyment PG, Vats T, Duncan MH. Modified LSA2-L2 treatment in 53 children with E-rosette positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group study). Blood 1982; 60: 1159-1168.
36. Sullivan MP, Boyett J, Pullen J, Crist W, Doering EJ, Trueworthy R, Hvizdala E, Ruymann F, Steuber CP. Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded). Cancer 1985; 55: 323-336.
37. Hvizdala EV, Berard C, Callihan T, Falletta J, Sabio H, Shuster JJ, Sullivan M, Wharam MD. Lymphoblastic lymphoma in children -a randomized trial comparing LSA2-L2 with the ACOP+ therapeutic regimen: a Pediatric Oncology Group study. J Clin Oncol 1988; 6: 26-33.
38. Falletta JM, Shuster JJ, Crist WM, Pullen DJ, Borowitz MJ, Wharam M, Patterson R, Foreman E, Vietti TJ. Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study. Leukemia 1992; 6: 541-546.
39. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980; 7: 332-339.
40. Steuber CP, Levy GJ, Nix WL, Shepherd DA, Starling KA, Fernbach DJ. Use of L-asparaginase and cytosine arabinoside for refractory acute lymphocytic leukemia with particular reference to T-cell leukemia. Med Pediatr Oncol 1978; 5: 33-38.
41. Dahl GV, Rivera G, Pui CH, Mirro J Jr, Ochs J, Kalwinsky DK, Abromowitch M, Look AT, Murphy SB. A novel treatment of childhood lymphoblastic non-Hodgkin's lymphoma: early and intermittent use of teniposide plus cytarabine. Blood 1985; 66: 1110-1114.
42. Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell NJ, Blattner SR, Tantravaki R, Leavitt P, Sallan SE. Four agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. New Engl J Med 1986; 315: 657-663.
43. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
44. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1-39.
45. Amylon MD, Carroll AJ, Link MP, Katz JA, Shuster JJ. Second malignancies in children treated with teniposide (VM-26) for T-cell lymphoid malignancy: a role for asparaginase? (A Pediatric Oncology Group study). Blood 1992; 80 (Suppl. 1): 206a.
46. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE. Treatment of childhood acute lymphoblastic leukemia: results of a Dana-Farber Cancer Institute/Children's Hospital acute lymphoblastic leukemia consortium protocol 85-01. J Clin Oncol 1994; 12: 740-747.
47. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients, results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133.
48. Tubergen DG, Krailo MD, Meadows AT, Rosenstock J, Kadin M, Morse M, King D, Steinherz PG, Kersey JH, Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. J Clin Oncol 1995; 13: 1368-1376.
49. Pui CH, Crist WM. Biology and treatment of acute lymphoblastic leukemia. J Pediatr 1994; 124: 491-503.
50. Albain KS, LeBeau MM, Ullirsch R, Schumacher H. Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy related monocytic leukemia with a 9; 11 translocation. Genes Chromosomes Cancer 1990; 2: 53-58.
51. Whitlock JA, Greer JP, Lukens JN. Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia. Cancer 1991; 68: 600-604.
52. Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, Mahmoud MH, Sandlund JT, Crist WM. Acute myeloid leukemia in children treated with epipodo-phyllotoxins for acute lymphoblastic leukemia. New Engl J Med 1991; 325: 1682-1687.
53. Ratain MJ, Rowley JD. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol 1992; 3: 107-111.
54. Hunger SP, Tkachuk DC, Amylon MD, Link MP, Carroll AJ, Welborn JL, Cleary ML. HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities. Blood 1993; 81: 3197-3203.
55. Grunwald HW, Rosner F. Acute myeloid leukemia following treatment of Hodgkin's disease. Cancer 1982; 50: 676-683.
56. Pedersen-Bjergaard J, Larsen SO. Incidence of acute non-lymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. New Engl J Med 1982; 307: 965-971.
57. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. New Engl J Med 1988; 318: 76-81.
58. Harris MB, Shuster JJ, Pullen DJ, Borowitz MJ, Carroll AJ, Behm FG, Land VJ. Consolidation with anti-metabolite based therapy in standard risk acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1998; 16: 2840-2847.